Provided by Tiger Trade Technology Pte. Ltd.

Pfizer

28.00
+0.50001.82%
Pre-market: 27.99-0.0144-0.05%07:02 EDT
Volume:31.23M
Turnover:874.14M
Market Cap:159.20B
PE:36.85
High:28.17
Open:27.62
Low:27.55
Close:27.50
52wk High:29.21
52wk Low:23.62
Shares:5.69B
Float Shares:5.64B
Volume Ratio:1.00
T/O Rate:0.55%
Dividend:1.72
Dividend Rate:6.14%
EPS(TTM):0.7599
EPS(LYR):1.36
ROE:5.01%
ROA:5.78%
PB:1.87
PE(LYR):20.52

Loading ...

Pfizer - Phase 2 Study Meets Primary Endpoint with Significant Easi-75 Improvement at Week 16

THOMSON REUTERS
·
Oct 01

23% Weight Loss, 27% Dropouts: How Strong Is Lilly's Phase 2 Combo, Really?

Options & Short Sell
·
Oct 01

NYSE Most Active Issues

Dow Jones
·
Oct 01

Abbott Laboratories Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Oct 01

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 30

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 29

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

THOMSON REUTERS
·
Sep 29

Pfizer Gets Tax Penalty of 12.6 Million Rupees

Reuters
·
Sep 29

$20 Billion In Deals And Counting: Lilly's CEO Targets The "White Space" Of Science For Larger M&A

Options & Short Sell
·
Sep 29

Judge Rejects Pfizer, BioNTech, and Moderna Bid to Dismiss Monsanto mRNA Patent Lawsuit

Stock News
·
Sep 29

How Investors May Respond To Pfizer (PFE) ESMO Cancer Data Showcase

Simply Wall St.
·
Sep 29

AstraZeneca To Invest $2 Billion In Summit And Co-Develop Drugs; Shares Jump After Hours

Options & Short Sell
·
Sep 29

Pfizer, Moderna Lose Bids to Escape Bayer US mRNA Patent Lawsuit

Reuters
·
Sep 29

Pfizer's Tilrekimig Phase 3 Program Seen as Potential Upside Driver, UBS Says

MT Newswires Live
·
Sep 28

US Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 28

Pfizer to Present Phase 3 SigVie-002 Survival Data for Sigvotatug Vedotin in Previously Treated NSCLC at ESMO 2026

Reuters
·
Sep 28

Pfizer (PFE) Bets Big on RSV and Cancer Care

TIPRANKS
·
Sep 26

NYSE Most Active Issues

Dow Jones
·
Sep 26

Pfizer Targets Cancer-Related Weight Loss With New Ponsegromab Study

TIPRANKS
·
Sep 26

Pfizer’s RSV Revaccination Trial Targets Durable Booster Revenue in High‑Risk Adults

TIPRANKS
·
Sep 26